Chromosomal catastrophe is a frequent event in clinically insignificant prostate cancer

Oncotarget

Volumn 6, Issue 30, 2015, Pages 29087-29096

  Kovtun, Irina V ^a,b   Murphy, Stephen J ^b   Johnson, Sarah H ^b   Cheville, John C ^b   Vasmatzis, George ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Catastrophe; Chromothripsis; Genomic rearrangements; Gleason score; Prostate cancer

Indexed keywords

ARTICLE; CANCER GRADING; CANCER GROWTH; CHROMOSOME FRAGILE SITE; CHROMOSOME REARRANGEMENT; CHROMOSOME SIZE; CHROMOTHRIPSIS; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE FREQUENCY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SEQUENCE ANALYSIS; CHROMOSOME ABERRATION; COPY NUMBER VARIATION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENETIC PREDISPOSITION; GENETICS; HUMAN CHROMOSOME; PATHOLOGY; PROSTATE TUMOR;

ERG PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR ERG; TUMOR MARKER;

BIOMARKERS, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOME FRAGILE SITES; CHROMOSOMES, HUMAN; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASM GRADING; PHENOTYPE; PROSTATIC NEOPLASMS; TRANS-ACTIVATORS; TRANSCRIPTIONAL REGULATOR ERG;

EID: 84945156303     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4900     Document Type: Article

References (40)

1. Jones M, Jallepalli PV. Chromothripsis: chromosomes in crisis. Dev Cell. 2012; 23:908-917.
2. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin ML, McBride DJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell. 2011; 144:27-40.
3. Kloosterman WP, Hoogstraat M, Paling O, TavakoliYaraki M, Renkens I, Vermaat JS, van Roosmalen MJ, van Lieshout S, Nijman IJ, Roessingh W, van't Slot R, van de Belt J, Guryev V, et al. Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancer. Genome Biol. 2011; 12:R103.
4. Magrangeas F, Avet-Loiseau H, Munshi NC, Minvielle S. Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood. 2011; 118:675-678.
5. Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, Hamdi M, van Nes J, Westerman BA, van Arkel J, Ebus ME, Haneveld F, Lakeman A, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012; 483:589-593.
6. Hirsch D, Kemmerling R, Davis S, Camps J, Meltzer PS, Ried T. Chromothripsis and focal copy number alterations determine poor outcome in malignant melanoma. Cancer Res. 2013; 73:1454-1460.
7. Rausch T, Jones DT, Zapatka M, Stütz AM, Zichner T, Weischenfeldt J, Jäger N, Remke M, Shih D, Northcott PA, Pfaff E, Tica J, Wang Q, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012; 148:59-71.
8. Korbel J, Campbell PJ. Criteria for inference of chromothripsis in cancer genomes. Cell. 2013; 152:1226-1236.
9. Forment JV, Kaidi A, Jackson SP. Chromothripsis and cancer: causes and consequences of chromosome shattering. Nat Rev Cancer. 2012; 12:663-670.
10. Chiang C, Jacobsen JC, Ernst C, Hanscom C, Heilbut A, Blumenthal I, Mills RE, Kirby A, Lindgren AM, Rudiger SR, McLaughlan CJ, Bawden CS, Reid SJ, et al. Complex reorganization and predominant non-homologous repair following chromosomal breakage in karyotypically balanced germline rearrangements and transgenic integration. Nat Genet. 2012; 44:390-397.
11. Feenstra I, Hanemaaijer N, Sikkema-Raddatz B, Yntema H, Dijkhuizen T, Lugtenberg D, Verheij J, Green A, Hordijk R, Reardon W, Vries Bd, Brunner H, Bongers E, et al. Balanced into array: genome-wide array analysis in 54 patients with an apparently balanced de novo chromosome rearrangement and a meta-analysis. Eur J Hum. Genet. 2011; 19:1152-1160.
12. Kloosterman W, Cuppen E. Chromothripsis in congenital disorders and cancer: similarities and differences. Curr Opin Cell Biol. 2013; 25:341-348.
13. Gribble SM, Prigmore E, Burford DC, Porter KM, Ng BL, Douglas EJ, Fiegler H, Carr P, Kalaitzopoulos D, Clegg S, Sandstrom R, Temple IK, Youings SA, et al. The complex nature of constitutional de novo apparently balanced translocations in patients presenting with abnormal phenotypes. J Med Genet. 2005; 42:8-16.
14. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, et al. The genomic complexity of primary human prostate cancer. Nature. 2011; 470:214-220.
15. Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013; 153:666-677.
16. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310:644-648.
17. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM. Integrative molecular concept modeling of prostate cancer progression. Nat Genet. 2007; 39:41-51.
18. Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2012; 24:1967-2000.
19. Kovtun IV, Cheville JC, Murphy SJ, Johnson SH, Zarei S, Kosari F, Sukov WR, Karnes RJ, Vasmatzis G. Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. Cancer Res. 2013; 73:3275-3284.
20. Lapuk AV, Wu C, Wyatt AW, McPherson A, McConeghy BJ, Brahmbhatt S, Mo F, Zoubeidi A, Anderson S, Bell RH, Haegert A, Shukin R, Wang Y, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 2012; 227:286-297.
21. Wu C, Wyatt AW, McPherson A, Lin D, McConeghy BJ, Mo F, Shukin R, Lapuk AV, Jones SJ, Zhao Y, Marra MA, Gleave ME, Volik SV, et al. Poly-gene fusion transcripts and chromothripsis in prostate cancer. Genes Chromosomes Cancer. 2012; 51:1144-1153.
22. Murphy SJ, Cheville JC, Zarei S, Johnson SH, Sikkink RA, Kosari F, Feldman AL, Eckloff BW, Karnes RJ, Vasmatzis G. Mate pair sequencing of whole-genomeamplified DNA following laser capture microdissection of prostate cancer. DNA Res. 2012; 19:395-406.
23. Drucker TM, Johnson SH, Murphy SJ, Cradic KW, Therneau TM, Vasmatzis G. BIMA V3: an aligner customized for mate pair library sequencing. Bioinformatics. 2014; 30:1627-1629.
24. Edwards J, Krishna NS, Witton CJ, Bartlett JM. Gene amplifications associated with the development of hormoneresistant prostate cancer. Clin Cancer Res. 2003; 9:5271-5281.
25. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. 2007; 31:882-888.
26. Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene. 2007; 26:7773-7779.
27. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogeneinduced DNA damage model for cancer development. Science. 2008; 319:1352-1355.
28. Dillon LW, Burrow A.A, Wang Y.H. DNA instability at chromosomal fragile sites in cancer. Genomics. 2010; 11:326-337.
29. Smith DI, McAvoy S, Zhu Y, Perez DS. Large common fragile site genes and cancer. Semin Cancer Biol. 2007; 17:31-41.
30. Fungtammasan A, Walsh E, Chiaromonte F, Eckert KA. A genome-wide analysis of common fragile sites: what features determine chromosomal instability in the human genome? Genome Res. 2012; 22:993-1005.
31. Mrasek K, Schoder C, Teichmann AC, Behr K, Franze B, Wilhelm K, Blaurock N, Claussen U, Liehr T, Weise A. Global screening and extended nomenclature for 230 aphidicolin-inducible fragile sites, including 61 yet unreported ones. Int J Oncol. 2010; 36:929-940.
32. Mortusewicz O, Herr P, Helleday T. Early replication fragile sites: where replication-transcription collisions cause genetic instability. EMBO J. 2013; 32:493-495.
33. Aguilera A, Gómez-González B. Genome instability: a mechanistic view of its causes and consequences. Nat Rev Genet. 2008; 9:204-217.
34. Kloosterman WP, Koster J, Molenaar JJ. Prevalence and clinical implications of chromothripsis in cancer genomes. Curr Opin Oncol. 2014; 26:64-72.
35. Wilson TE, Arlt MF, Park SH, Rajendran S, Paulsen M, Ljungman M, Glover TW. Large transcription units unify copy number variants and common fragile sites arising under replication stress. Genome Res. 2014.
36. Saksela K, Arlt MF, Park SH, Rajendran S, Paulsen M, Ljungman M. Amplification of the c-myc oncogene in a subpopulation of human small cell lung cancer. Cancer Res. 1985; 45:1823-1827.
37. Bednarek AK, Bednarek AK. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res. 2001; 61:8068-8073.
38. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996; 84:587-597.
39. Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, Leongamornlert DA, Tymrakiewicz M, Jhavar S, Saunders E, Hopper JL, Southey MC, Muir KR, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet. 2009; 41:1058-1060.
40. Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R, Viswanatha DS, Law ME, Kip NS, Ozsan N, Grebe SK, Frederick LA, Eckloff BW, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012; 120:2280-2289.